Bright Biologics is pleased to announce that its abstract, “The Anti-Tumor Activity of BB-202, a Novel Anti-PD-1/Anti-VEGF Bispecific Antibody,” has been accepted for presentation at the AACR 2026 Annual Meeting, to be held April 17–22 in San Diego.
BB-202 is a novel bispecific antibody engineered with an anti-PD-1 arm derived from Keytruda and a potent anti-VEGFA VHH arm discovered in-house. In vitro studies demonstrate that BB-202 achieves comparable potency to Keytruda in PD-1 blockade and to Avastin in VEGFA inhibition. Preclinical data further indicate enhanced anti-tumor efficacy across multiple cancer models compared to the monospecific PD-1 antibody Keytruda.
In a dose-range finding (DRF) toxicity study in cynomolgus monkeys, BB-202 was well tolerated at doses up to 100 mg/kg.
By simultaneously targeting PD-1 and VEGFA within a single molecule, BB-202 is designed to enhance the synergistic effects of immune checkpoint inhibition and anti-angiogenesis. Notably, BB-202 demonstrated approximately 20–30-fold greater anti-PD-1 potency compared to the leading bispecific antibody in this class, Ivonescimab. This enhanced potency may help address limitations associated with insufficient PD-1 blockade reported for Ivonescimab in clinical studies, where no significant improvement in overall survival (OS) versus Keytruda has been observed.
BB-202 is currently advancing through CMC development. The company expects to initiate IND-enabling studies in the near term, with IND submission anticipated by the end of 2026.
BB-202 will be presented as a poster on April 21, 2026, in the “Bi- and Tri-Specific Antibody Therapies” session (Poster #5539).
